Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-408-1300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$49.99 million
Profitability
Miscellaneous
Employees215
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics Inc (NASDAQ:NEOS) released its earnings results on Thursday, August, 8th. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.09. The company had revenue of $15.64 million for the quarter, compared to analyst estimates of $16.70 million. View Neos Therapeutics' Earnings History.
When is Neos Therapeutics' next earnings date?
What price target have analysts set for NEOS?
4 brokers have issued 1-year price objectives for Neos Therapeutics' stock. Their predictions range from $3.00 to $10.00. On average, they anticipate Neos Therapeutics' stock price to reach $7.25 in the next year. This suggests a possible upside of 410.6% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.
What is the consensus analysts' recommendation for Neos Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.
Has Neos Therapeutics been receiving favorable news coverage?
Press coverage about NEOS stock has been trending very negative on Thursday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neos Therapeutics earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Neos Therapeutics.
Are investors shorting Neos Therapeutics?
Neos Therapeutics saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,990,000 shares, a decrease of 5.2% from the August 30th total of 2,100,000 shares. Based on an average daily volume of 199,800 shares, the short-interest ratio is presently 10.0 days. Approximately 4.1% of the company's stock are short sold. View Neos Therapeutics' Current Options Chain.
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Kindred Biosciences (KIN), Cyclerion Therapeutics (CYCN), Molecular Templates (MTEM), BIOFRONTERA AG/ADR (BFRA), Recro Pharma (REPH), Puma Biotechnology (PBYI), Forty Seven (FTSV), resTORbio (TORC), Seres Therapeutics (MCRB), ProQR Therapeutics (PRQR), MannKind (MNKD) and Stealth BioTherapeutics (MITO).
What other stocks do shareholders of Neos Therapeutics own?
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Mr. Richard I. Eisenstadt, CFO, Treasurer & Corp. Sec. (Age 61)
- Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 51)
- Mr. John P. Limongelli, Sr. VP & Gen. Counsel (Age 49)
- Mr. Darren Heath, VP of Sales
- Mr. Russ McMahen, Sr. VP of R&D
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.
How do I buy shares of Neos Therapeutics?
Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of NEOS stock can currently be purchased for approximately $1.42.
How big of a company is Neos Therapeutics?
Neos Therapeutics has a market capitalization of $70.62 million and generates $49.99 million in revenue each year. The company earns $-51,670,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.View Additional Information About Neos Therapeutics.
What is Neos Therapeutics' official website?
How can I contact Neos Therapeutics?
Neos Therapeutics' mailing address is 2940 N. HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]
MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
